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The potential contribution of tumour-related
factors to the development of FOLFOX-induced
sinusoidal obstruction syndrome
S M Robinson*,1,2, D A Mann2, D M Manas1, F Oakley2, J Mann2,3 and S A White1,2,3
1Department of HPB Surgery, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK and 2Institute of Cellular Medicine,
Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
Background: Chemotherapy-associated liver injury (CALI) has been linked to increased morbidity and poorer disease-specific
outcomes in patients undergoing resection of colorectal liver metastases (CRLM). The aim of this study was to assess the
contribution of tumour-related factors to the development of FOLFOX-induced liver injury.
Methods:We assessed the effect of FOLFOX treatment on the murine liver either in the presence or absence of CRLM to evaluate
the contribution of both chemotherapy and tumour death to the development of CALI.
Results: In the presence of liver metastases, there was increased hepatic expression of plasminogen activator inhibitor-1 (146-fold;
Po0.01) and vWF (2.4-fold; Po0.01) transcript as compared with sham-operated controls. In addition, we detected large clusters
of megakaryocytes in the spleen of FOLFOX-treated tumour-bearing animals. The livers of FOLFOX-treated animals also showed
changes in matrix remodelling genes such as TGFb (Po0.01), MMP2 (Po0.001), TIMP1 (Po0.001) and Pro-Collagen I (Po0.05)
which was exacerbated in the presence of tumour. These genes have previously been demonstrated to have a key role in
FOLFOX-induced liver injury.
Conclusion: It appears that the toxicity of FOLFOX chemotherapy is enhanced by tumour-related factors.
Colorectal cancer is the second leading cause of cancer-related
death in the western world. Up to 50% of patients with colorectal
cancer will develop liver metastases and in 25% of patients are
present at the time of primary diagnosis (Stangl et al, 1994).
Resection is the gold standard treatment for colorectal liver
metastases (CRLM) with 5-year survival in the order of 50–60%
being achievable (Rees et al, 2008). Unfortunately a significant
proportion of patients are not suitable for surgery at the time of
presentation and require neoadjuvant chemotherapy with the aim
of down-staging their disease such that they become operable. In
those patients successfully down-staged long-term survival can be
achieved which is comparable with those patients offered surgery
from the outset (Alberts et al, 2005).
The most commonly used chemotherapy for CRLM consists of
folinic acid/5-FU (or the oral pro-drug Capecitabine) in combina-
tion with either Oxaliplatin (FOLFOX) or Irinotecan (FOLFIRI)
both of which have widely proven efficacy in down-staging CRLM
(Robinson et al, 2009). Nonetheless these regimens are associated
with the development of chemotherapy-associated liver injury
(CALI). The nature of the injury appears to be regimen specific
with FOLFIRI being associated with steatohepatitis, whereas
FOLFOX is linked to the development of sinusoidal obstruction
syndrome (SOS) and nodular regenerative hyperplasia (Robinson
et al, 2009; Rubbia-Brandt et al, 2010). The presence of any
underlying hepatic parenchymal disease increases the risk of post-
operative hepatic insufficiency and as such the presence of CALI is
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a cause of major concern when undertaking more extensive
resections (de Meijer et al, 2010). In addition, CALI has been
linked to poorer long-term disease-specific outcomes (Tamandl
et al, 2011).
Increasingly an ever more aggressive approach is being taken to
the management of CRLM with increasing numbers of patients
undergoing second and third resections for recurrent disease
(Adam et al, 1997; Adam et al, 2003). Frequently these procedures
are interspersed with repeated cycles of chemotherapy meaning
that CALI is becoming an ever more pressing issue facing the
surgeon managing this cohort of patients. Understanding the
pathogenesis of this condition would enable the identification of
therapeutic strategies to reduce the incidence of this complication
of chemotherapy and thereby improve the safety of surgery in this
cohort of patients.
Several authors have attempted to investigate the pathogenesis
of this condition using human tissue obtained at the time of liver
resection (Pilgrim et al, 2011; Rubbia-Brandt et al, 2011; Agostini
et al, 2012). The limitation of this approach is that although it
provides an understanding of the ultimate effect of chemotherapy
administration on the liver, it does not enable one to investigate the
biological mechanisms resulting in these changes or how their
manipulation may impact on subsequent liver injury. To do this, a
realistic in vivo experimental model is required which reflects, as
closely as possible, the events occurring in patients. To this end, we
recently developed a murine model of chemotherapy-induced liver
injury which enabled us to identify a number of the key
pathological processes involved in the pathogenesis of Oxaliplatin-
induced SOS (Robinson et al, 2013).
Data from two cohort studies have suggested that tumour-
related factors may contribute to the development of SOS
(Soubrane et al, 2010; Tamandl et al, 2011). The aim of this study
was to determine what impact tumour-related factors might have
on Oxaliplatin-induced SOS.
MATERIALS AND METHODS
All animal studies were subject to review and approval by the local
research ethics committee and the UK home office. The use of
human tissue for research was approved by the NHS research
ethics committee (reference 11/NE/0009 & 07/Q0906/15) and
informed consent was obtained from all participants.
In vitro chemotherapy model. The MCA38 colorectal cancer cell
line was a gift from Dr Mario Paolo Colombo (Istitutio Tumori,
Milan, Italy). Cells were cultured in Dulbecco’s modified eagle
medium supplemented with 10% fetal calf serum, 100Uml 1
Penicillin, 100 mgml 1 Streptomycin and 2mM L-Glutamine.
The IC50 concentration of Oxaliplatin (7mM) and 5-FU (14 mM)
at 48 h were determined by MTT assay. When treating MCA38
cells with FOLFOX, they were seeded and allowed to adhere
overnight before exchanging media for that supplemented with
10 mM folinic acid. Oxaliplatin was then added followed by 5-FU
2 h later (Fischel et al, 2002).
Hepatic tumour implantation. C57Bl/6 mice were subject to
laparotomy under isoflurane anaesthesia. In all, 1 105 MCA38
cells stably transfected with the pGL4.51 luciferase reporting vector
(Promega, Southampton, UK) were then injected beneath the
capsule of the left lobe of the liver in 10 ml of Hanks buffered salt
solution. Haemostasis was achieved by manual compression and
the injection track sealed with butylcyanoacrylate glue (Indermil,
Henkel Ltd, Hatfield, UK). Animals were allowed to recover for
5 days before the administration of chemotherapy. Sham-operated
controls underwent laparotomy only.
The FOLFOX chemotherapy regimen consisted of weekly cycles
of intraperitoneal (i.p.) FOLFOX consisting of 6mg kg 1
Oxaliplatin followed 2 h later by 50mg kg 1 5-FU and 90mg kg 1
folinic acid. This drug-dosing schedule was based upon a careful
review of the literature and has been previously used within our
unit to induce histological changes of SOS in C57BL/6 J mice after
5 weeks of treatment. Control animals were treated with vehicle
alone (Boughattas et al, 1989; Cao et al, 1996; Keizman et al, 2010;
Robinson et al, 2013).
Tumour-bearing mice and sham-operated controls were treated
with IP FOLFOX, or vehicle control, giving a total of four groups of
animals (n¼ 6 per group). The treatment protocol had to be
terminated one day after the third treatment owing to large tumour
size in the control animals and significant weight loss in the
FOLFOX-treated group.
Tumour size in culled animals was assessed using the tumour to
body weight ratio (tumour weight/pre-mortem body weight) and
by estimating the tumour volume (tumour width2 tumour
length 0.5).
Patient tissue collection. A 1-cm3 segment of non-tumour-
bearing liver tissue was collected from patients undergoing elective
liver resection and stored in RNA later (Sigma-Aldrich, Dorset,
UK) prior to storage at  80 1C. Biopsies were taken immediately
after opening the abdomen prior to commencing parenchymal
transaction or vascular inflow occlusion. Clinical data including the
use of pre-operative chemotherapy were recorded for each patient.
Histology reports from these patients were reviewed to identify
those with evidence of vascular injury to the hepatic parenchyma
in keeping with a diagnosis of SOS. Patients with underlying
chronic liver disease or primary liver tumours were excluded from
analysis.
Three groups of patients were identified for subsequent
analysis – those who were chemotherapy naive (n¼ 10); those
who received pre-operative Oxaliplatin-based chemotherapy but
had no evidence of vascular injury (n¼ 9) and those who received
pre-operative chemotherapy and had an identifiable vascular injury
(n¼ 13).
RNA extraction, cDNA synthesis and qRT–PCR. Total RNA was
extracted using the RNeasy purification system (Qiagen, Manchester,
UK). One microgram of total RNA was used to generate cDNA
using MMLV-RT and a random hexamer primer (Promega).
Quantitative real-time PCR (qRT–PCR) was performed using
SYBR-green reagents (Sigma-Aldrich). GAPDH was used as the
internal control.
Immunohistochemistry. Sections were deparaffinised and endo-
genous peroxidase activity blocked. Following antigen retrieval,
non-specific binding was inhibited by using the avidin/biotin
blocking kit (Vector Laboratories, Burlingame, CA, USA) followed
by incubation for 30min with 20% swine serum. Primary
antibodies were added and sections incubated overnight at 4 1C.
The following morning sections were washed then incubated with
an appropriate biotin-conjugated secondary antibody for 2 h then
washed and further incubated for 1 h with Streptavidin Biotin-
Peroxidase Complex (Vector Laboratories). Positive cells were
visualised with 3,30-diaminobenzidine tetrahydrochloride (DAB)
(Vector Laboratories) and counterstained with haematoxylin.
Sections were blinded and the number of positive cells was
counted in 15 high-power fields (HPFs).
CXCL1 ELISA/extracellular ATP assay cell culture supernatants.
Supernatant was harvested from MCA38 cells treated with
FOLFOX chemotherapy, or vehicle control, for 24 h and snap
frozen at  80 1C. CXCL1 was measured in the cell culture
supernatants using a CXCL1 DuoSet ELISA Development Kit
(R&D Systems, Abingdon, UK).
Statistical analysis. Numerical data are expressed as mean
value±s.e.m. Statistical significance was assessed using
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Mann–Whitney U-test and Kruskall–Wallis one-way analysis of
variance as appropriate for in vivo data. A two-tailed Student’s
t-test was used for in vitro qRT–PCR data. A P-value ofo0.05 was
considered to be statistically significant.
RESULTS
FOLFOX treatment of colorectal tumour cells activates
inflammatory signalling. Recent reports have suggested that
cancer cell death by Oxaliplatin-induced apoptosis may not be
an immunologically silent event but rather may result in the local
release of a variety of pro-inflammatory mediators (Tesniere et al,
2008). To explore whether these tumour-produced mediators
might contribute to Oxaliplatin-induced liver injury, it was decided
to establish experimental CRLM in C57/Bl6 mice with the
syngeneic MCA38 colorectal cancer cell line.
Prior to in vivo studies, death of MCA38 cells in response to
FOLFOX was confirmed in vitro (Figure 1A). In addition, it was
observed that FOLFOX-induced expression of chemokines associated
with inflammation and wound-repair responses (Figure 1B).
A greater than 30-fold increase in CXCL1 transcript (the murine
equivalent of IL-8) was confirmed by measuring a three-fold
increase in secretion of soluble CXCL1 protein (Figure 1C).
CXCL5, CCL2 and CCL5 chemokines were also induced by
FOLFOX indicative of cell-damage-associated activation of inflam-
matory gene expression in the culture.
We have previously reported that increased hepatic expression
of these chemokines appears to be implicated in the pathogenesis
of SOS in FOLFOX-treated C57BL/6J mice (Robinson et al, 2013).
It may be that their production of by apoptosing colorectal cancer
cells within the liver contributes further to this process and it was
elected to further test this hypothesis in vivo.
Combined tumour and FOLFOX therapy stimulates matrix
remodelling. Preliminary experiments demonstrated that 5 days
following hepatic implantation of 105 MCA-38 cells, a solid
tumour was detectable by IVIS imaging (Figure 2A) and on this
basis this was the time point at which treatment with FOLFOX, or
vehicle control, was commenced. The in vivo effectiveness of this
chemotherapy regimen was demonstrated by a marked reduction
in the tumour volume (Figure 2B; P¼ 0.063) and tumour to body
weight ratio (Figure 2C; P¼ 0.041) in FOLFOX-treated animals.
When untreated these tumours produced a large local mass arising
from the liver parenchyma (Figure 2D and E) and in some animals
lung metastases were detectable although this was a late event.
Significant weight loss in both FOLFOX groups indicated systemic
toxicity of the chemotherapy regimen (Figure 2F).
Neither H&E (Figure 2G) nor Reticulin (not shown)-stained
sections of the liver demonstrated sufficient changes to fit the
diagnostic criteria for SOS. We have previously demonstrated that
5 weeks of FOLFOX treatment is necessary in C57BL/6J mice to
induce histological changes of SOS and the absence of positive
findings in this regard is not surprising (Robinson et al, 2013).
Nevertheless, we elected to interrogate this model further to
determine if molecular changes within the liver implicated in the
pathogenesis of SOS were enhanced by the presence of tumour.
Matrix remodelling and the subsequent development of
sinusoidal fibrosis is a cardinal feature of SOS. Hepatic stellate
cells (HSCs) have pivotal roles in matrix remodelling, particularly
in hepatic fibrogenesis. During this process, quiescent HSCs
become activated whereby they take on a myofibroblast phenotype
and express smooth muscle a-actin (aSMA) and procollagen I.
Figure 3A shows that FOLFOX treatment of tumour-bearing mice
results in up-regulation of aSMA (P¼ 0.082) and procollagen I
(P¼ 0.009) transcripts when compared with sham-operated
vehicle controls, in a manner similar to that seen with mice which
developed the histological changes of SOS (Robinson et al, 2013).
This fibrogenic state was supported by a modest increase in
numbers of hepatic aSMAþ cells (7.1 vs 9.9 cells per HPF;
P¼ 0.015) as detected by immunohistochemistry (Figure 3B). In
order to confirm the relevance of increased aSMA in the
pathogenesis of Oxaliplatin-induced SOS, we performed qRT–PCR
on mRNA isolated from the non-tumour-bearing liver of patients
undergoing resection of CRLM. In those patients with Oxaliplatin-
induced vascular injury, we were able to demonstrate a significant
increase in expression of aSMA as compared with those receiving
Oxaliplatin who do not develop a vascular injury (P¼ 0.019;
Figure 3C).
A similar pattern was seen in the hepatic expression of tissue
inhibitor of metalloproteinases 1 (TIMP 1) transcript in
tumour-bearing FOLFOX-treated mice (Figure 3D; P¼ 0.004)
again in keeping with the process of matrix remodelling in SOS
that we have previously reported. It appears that this response is,
in part, driven by the master regulator TGFb1, the transcript
levels of which are maximally elevated in tumour-bearing
animals treated with FOLFOX (Figure 3E; P¼ 0.004). FOLFOX
treatment resulted in a 13-fold up-regulation of MMP2 in
tumour-bearing animals treated with FOLFOX (Po0.002),
whereas no change in expression was detectable in sham-
operated animals (Figure 3F).
Previous published data both from experimental animal studies
and human microarray studies have suggested that FOLFOX-
induced liver injury is associated with increased hepatic expression
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Figure 1. MCA38 cells were treated in vitro with FOLFOX. Cell death
in response to FOLFOX after 48 h treatment was confirmed by
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of angiogenic factors, in particular, VEGF-A and VEGF-C.
(Rubbia-Brandt et al, 2011; Robinson et al, 2013). The presence
of tumour itself was associated with a modest increase in hepatic
expression of VEGF-C (1.7-fold, P¼ 0.002), which was further
increased upon treatment with FOLFOX (2.3-fold; P¼ 0.002). It is
noteworthy that FOLFOX treatment alone had no effect on
VEGF-C expression (Figure 3G). In contrast to this, the presence
of tumour within the liver had no effect on the hepatic expression
of VEGF-A. Confirming the importance of angiogenesis in the
pathogenesis of SOS, we were able to demonstrate increased
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histological changes of SOS. (*¼Po0.05).
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expression of VEGF-C in patients with Oxaliplatin-induced
vascular injury (Figure 3H; P¼ 0.044).
Combined tumour and FOLFOX results in a prothrombotic
environment. Our previous work has demonstrated that activation
of the clotting cascade seems to have a role in the pathogenesis
of SOS (Robinson et al, 2013). As shown in Figure 4A, treatment of
tumour-bearing mice with FOLFOX is associated with a 146-fold
increase in expression of the pro-thrombotic plasminogen activator
inhibitor-1 (PAI-1; SERPINE1) transcript (P¼ 0.004) as well as a
more modest increase in expression of von Willebrand factor
(P¼ 0.004; Figure 4B). There was a trend towards elevated vWF
transcript in patients with Oxaliplatin-induced vascular injury
although this did not quite reach statistical significance (P¼ 0.059;
Figure 4C).
In keeping with previous reports, we were able to confirm that
FOLFOX administration results in the accumulation of large
clusters of megakaryocytes within the spleen of both sham-
operated and tumour-bearing animals treated with FOLFOX
(Figure 4D and E; Po0.05).
DISCUSSION
Until the advent of modern chemotherapy regimens, the only
recognised cause of SOS was the ingestion of pyrrolizidine
alkaloids. SOS was subsequently recognised as a clinical entity in
patients undergoing myeloablative chemotherapy prior to
bone marrow transplantation and, more recently, following
administration of platinum-based chemotherapy to patients
with CRLM (DeLeve et al, 2002). Until recently knowledge
regarding the pathogenesis of this disease was drawn
predominantly from the study of rats treated with monocrotaline
which results in rapid appearance of SOS-type lesions within the
liver (DeLeve et al, 1999).
Although the administration of monocrotaline may replicate
many of the histological changes seen in patients with CALI, it is
extremely unlikely that the stimulus driving these changes is in any
way similar. To address this, we have recently established a murine
model of FOLFOX-induced SOS that replicates the histological
changes seen in patients receiving this chemotherapy regimen. The
aim of the current study was to evaluate the potential contribution
of tumour-related factors to the development of SOS. Although on
this occasion, we were not able to replicate the histological features
of SOS, because of the need to terminate the model with due
regards to animal welfare, we have demonstrated that many of the
changes in gene expression associated with the development of this
condition are accelerated in tumour-bearing mice (Rubbia-Brandt
et al, 2011; Robinson et al, 2013).
One criticism of the current model may be that the route of
chemotherapy administration (i.p.) differs from that used in
patients and therefore may limit the development of histological
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changes within the liver. This route was chosen as repeated
intravenous administration of a compound to mice (e.g. via the tail
vein) is not practical owing to the high failure rate with this
technique and the need for animal restraint (Turner et al, 2011). It
has been previously demonstrated that the i.p. administration of
Oxaliplatin can lead to the development of neurotoxicity in mice
suggesting there is significant systemic drug absorption (Ta et al,
2009). Moreover, we have recently reported that administration of
i.p. FOLFOX to mice for 5 weeks does lead to the development of
the histological features of SOS (Robinson et al, 2013).
Pro-thrombotic changes in the sinusoidal endothelium have
been implicated in the development of SOS (Copple et al, 2002;
Rubbia-Brandt et al, 2011; Robinson et al, 2013). In particular,
elevated serum PAI-1 levels have been reported both in mice with
FOLFOX-induced SOS as well as bone marrow transplantation
patients who go on to develop SOS following myeloablative
chemotherapy (Kaleelrahman et al, 2003; Robinson et al, 2013).
The importance of this process is reflected in the relative success of
the fibrinolytic agent defibrotide in the treatment of SOS in bone
marrow transplant recipients (Benimetskaya et al, 2008). In
concordance with these findings, we see increased expression of
the PAI-1 and vWF genes in the liver of mice treated with
FOLFOX chemotherapy, particularly in the presence of tumour.
It is likely that the presence of megakaryocytes in both the
spleen and liver following FOLFOX treatment results in the release
of platelets directly into the portal venous system and may
contribute to the development of pro-thrombotic environment
within the injured hepatic sinusoid. Given these observations, it
may be that patients with particularly large tumours would benefit
from treatment with antiplatelet therapy such as Aspirin which it
has been suggested may reduce the incidence of SOS in
Oxaliplatin-treated patients (Brouquet et al, 2009).
Despite the absence of florid fibrosis in our model, we have
shown changes in gene expression in keeping with a classical
fibrogenic response that we have previously reported in the context
of FOLFOX-induced SOS (Robinson et al, 2013). It appears from
the current study that the increase in expression of matrix
remodelling genes is markedly exacerbated by the presence of
tumour within the liver. It is increasingly recognised that tumour
death in response to many cytotoxic agents is not a silent event but
rather is associated with the production of a wide variety of
mediators that are capable of producing an inflammatory response
(Tesniere et al, 2008; Martins et al, 2009).
One example of how inflammatory mediator production by
dying tumour cells may contribute to the development of SOS is
provided by the chemokine CXCL1, the murine equivalent of IL-8,
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which is abundantly produced by FOLFOX-treated MCA38 cells
and is also elevated in the serum of patients with SOS (Remberger
and Ringden, 1997; Schots et al, 2003). CXCL1 exerts its effects on
endothelial cells via the CXCR2 receptor with resultant increased
expression of genes involved in angiogenesis such as MMP2 and
VEGF (Li et al, 2003; Li et al, 2005). In addition, IL-8 signalling to
human endothelial cells may increase further expression of pro-
thrombotic genes such as PAI-1 (Cheng et al, 2008). The
observation that patients with a larger tumour burden are more
likely to develop SOS, despite a similar number of cycles of
chemotherapy, would seem to support the concept that tumour
death contributes to SOS development (Tamandl et al, 2011).
The ideal strategy for patients with CRLM receiving
pre-operative FOLFOX-based chemotherapy would be to administer
a drug for the duration of the chemotherapy that prevents the
development of SOS. The use of antioxidants, particular those
which activate the transcription factor NRF2, alongside
chemotherapy has shown merit in this regard in experimental
models (Wang et al, 2000; Robinson et al, 2013). It may be that this
approach would be of particular value in those individuals with
a large tumour burden needing prolonged treatment with
pre-operative chemotherapy.
In conclusion, we have developed an experimental model which
demonstrates that the development of SOS in patients with CRLM
is likely to be multifactorial and supports the notion that tumour-
related factors may also contribute to this process.
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